Compare HIFS & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIFS | LBRX |
|---|---|---|
| Founded | 1834 | 2015 |
| Country | United States | United States |
| Employees | 97 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 602.6M |
| IPO Year | N/A | N/A |
| Metric | HIFS | LBRX |
|---|---|---|
| Price | $289.55 | $26.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $50.67 |
| AVG Volume (30 Days) | 47.0K | ★ 220.4K |
| Earning Date | 01-16-2026 | 05-09-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $209.71 | $13.40 |
| 52 Week High | $338.00 | $27.55 |
| Indicator | HIFS | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 63.49 |
| Support Level | $286.81 | $22.39 |
| Resistance Level | $290.40 | $27.55 |
| Average True Range (ATR) | 9.57 | 1.52 |
| MACD | 2.99 | 0.17 |
| Stochastic Oscillator | 89.44 | 92.74 |
Hingham Institution for Savings is a Massachusetts-chartered savings bank headquartered in Hingham, Massachusetts. The bank is principally engaged in the business of commercial and residential real estate mortgage lending, funded by a mix of retail and commercial deposits, wholesale deposits and borrowings. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending products are residential and commercial mortgage loans secured by properties in eastern Massachusetts. The bank also lends to commercial and residential real estate borrowers and services deposits for customers in the greater Washington, D.C. metropolitan area (WMA) and in the San Francisco Bay Area.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.